Common use of Publications Clause in Contracts

Publications. Pfizer shall not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information).

Publications. Pfizer shall not submit for Each Party to this Agreement recognizes that the publication or presentationof papers regarding results of the Research Collaboration, or publish or presentincluding oral presentations and abstracts, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (may be beneficial to the extent both Parties provided such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not publications are subject to be unreasonably withheld or delayed. During the Term, Iterum shall submit reasonable controls to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s protect Confidential Information. Such review will be conducted for In particular, it is the purposes of preserving the value intent of the Licensed Technology and determining whether Parties to maintain the confidentiality of any portion Confidential Information regarding results of the proposed publication HTS or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have other information regarding the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such Research Compounds included in any foreign patent application [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not until such foreign patent application has been published. Accordingly, each Party shall have the right to be unreasonably withheld or delayedreview and approve any paper proposed for publication by the other Party regarding results of the Research Collaboration hereunder, including oral presentations and abstracts, which utilizes data generated from the Research Collaboration and/or includes Confidential Information of the other Party. Written copies Before any such paper is submitted for publication, the Party proposing publication shall deliver a complete copy to the other Party at least [ * ] prior to submitting the paper to a publisher. The receiving Party shall review any such paper and give its comments to the publishing Party within [ * ] of the delivery of such proposed publication or paper to the receiving Party. With respect to oral presentation required materials, the Parties shall make reasonable efforts to be submitted hereunder expedite review of such materials, and shall be submitted return such items as soon as practicable to Pfizer the disclosing Party with appropriate comments, if any, but in no event later than [ * ] before submission for publication or presentation (from the “Review Period”)date of delivery to the receiving Party. Pfizer The disclosing Party shall provide its comments comply with respect the other Party's request to delete references to such publications other Party's Confidential Information in any such paper and presentations within [ * ] agrees to withhold publication of its receipt of such written copy. The Review Period may be extended same for an additional [ * ] in order to permit the event Pfizer canParties to obtain patent protection, within [ * ] of receipt if either of the written copyParties deem it necessary, demonstrate reasonable need for in accordance with the terms of this Agreement. If there is a dispute regarding publications, such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum dispute shall be free to publish and present all Developed IP generated resolved by the Research Management Committee or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement if the Research Management Committee has been terminated dissolved, by the Officers in any country or countries by Pfizer pursuant to accordance with Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)17.2.

Publications. Pfizer shall not submit for INS recognizes that the publication or presentationof papers by ViroPharma regarding results of and other information regarding activities under this Agreement, or publish or presentincluding oral presentations and abstracts, any academicmay be beneficial to both Parties, scientific or medical publication or presentation disclosing provided such publications are subject to reasonable controls to protect Confidential Information and avoid loss of potentially patentable rights in Improvements. In particular, it is the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value intent of the Licensed Technology and determining whether Parties to maintain the confidentiality of any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deletedincluded in any Patent application until such Patent application has been filed. Pfizer Accordingly, INS shall have the right to review and approve any paper proposed for publication by ViroPharma, including any oral presentation or abstract, which includes INS’s Confidential Information. Before any such proposed publications paper is submitted for publication or an oral presentation is made, ViroPharma shall deliver a complete copy of the paper or materials for oral presentation to INS at least thirty (30) days prior to submitting the paper to a publisher or making the presentation. INS shall review any such paper and give its comments to ViroPharma within twenty (20) days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, INS shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to ViroPharma with appropriate comments, if any, but in no event later than twenty (20) days from the date of delivery to INS. Failure to respond within such Pfizertwenty (20) days shall be deemed approval to publish or present. If approval is not given or deemed given, ViroPharma may refer the Dispute in accordance with Section 13.7 for resolution. Notwithstanding the foregoing, ViroPharma shall comply with INS’s reasonable request to delete references to INS’s Confidential Information relates to [ * ], in any such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted paper and filed separately with the Securities and Exchange Commission pursuant to Rule 406 shall withhold publication of the Securities Act any such paper or any presentation of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended same for an additional [ * ] sixty (60) days in order to permit the event Pfizer can, within [ * ] of receipt Parties to obtain patent protection if either Party deems it necessary. Any publication shall include recognition of the written copycontributions of the other Party, demonstrate reasonable need and the contributions of Xxxxxx Chain to the Development of Licensed Products, according to standard practice for such extension including for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. For the preparation and filing avoidance of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in doubt, INS shall not publish any publication governed by this Section 14.3paper, including International Committee any oral presentation or abstract, which contains Clinical Data or pertains to the results of Medical Journal Editors standards regarding authorship Clinical trials or other studies relating to the Licensed Products and contributions. For clarity, Iterum shall be free to publish and present all Developed IP or the INS Technology or includes other Information generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizeror which includes ViroPharma’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information).

Publications. Pfizer Neither Party or its Affiliates shall publish or publicly disclose the results of any of the research and/or development activities conducted under the Research Program or under any Early Development Program, without the prior written consent of the other Party, except that after the end of the Research Term, the foregoing shall not submit apply to ChemoCentryx for publication or presentationresults that do not relate to any Collaboration Compounds, or to GSK for results that relate directly to any of the Product Candidates or Licensed Products. The Parties recognize that it may be useful or required to publish or presentpublicly disclose the results of development work on Licensed Products, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How and GSK (to the extent such Licensed Know-How is still Pfizer’s Confidential Informationand its Affiliates and Sublicensees) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish or publicly disclose such results, subject to the prior review by ChemoCentryx for patentability and present all Developed IP generated protection of its Confidential Information. GSK shall provide to ChemoCentryx at GSK’s earliest practical opportunity any proposed abstracts, manuscripts or summaries of presentations which cover the results of clinical development of any Licensed Product, for review and comment as to matters relating to its patents and Confidential Information. ChemoCentryx shall respond in writing promptly and in no event later than thirty (30) days after receipt of the proposed material, or within such reasonably shorter period as is required (and promptly communicated by GSK to ChemoCentryx) by the relevant publication deadline, with either approval of the proposed material or on behalf a specific statement of Iterum concern, based upon either the need to seek patent protection or its Affiliates concern regarding competitive disadvantage arising from the proposal. In the event of concern, GSK agrees not to submit such publication or Partners under this Agreement without Pfizer’s review or approval to make such presentation that contains such information until ChemoCentryx is given a reasonable period of time (unless this Agreement has been terminated not to exceed sixty (60) days) to seek patent protection for any material in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according which it believes is patentable or to resolve any other issues. This Section 9.6 shall cease to apply with respect to any Licensed Product upon the commercial launch of such Licensed Product. Furthermore, with respect to any proposed abstracts, manuscripts or summaries of presentations by investigators or other Third Parties, such materials shall be subject to review under this Section 9.6 to the procedures set forth in this Section 14.3 for publication extent that GSK or presentation of Pfizer Confidential Information)ChemoCentryx (as the case may be) has the right to do so.

Publications. Pfizer Except as provided in this Agreement, neither Party or its Affiliates shall publish or publicly disclose the results of any of the research and/or development activities conducted under this Agreement, without the prior written consent of the other Party, except that after the expiration of all Options, the foregoing shall not submit apply to Anacor for publication or presentationresults that relate to any Anacor Development Compounds, or to GSK for results that relate directly to any GSK Development Compounds. The Parties recognize that it may be useful or required to publish or presentpublicly disclose the results of development work on Products, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How and GSK (to the extent such Licensed Know-How is still Pfizer’s Confidential Informationand its Affiliates and Sublicensees) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum only shall be free to publish or publicly disclose such results, subject to the prior review by Anacor for patentability and present all Developed IP generated protection of its Confidential Information. GSK shall provide to Anacor at GSK's earliest practical opportunity any proposed abstracts, manuscripts or summaries of presentations which cover the results of clinical development of any Product, for review and comment as to matters relating to its patents and Confidential Information. Anacor shall respond in writing promptly and in no event later than [***] after receipt of the proposed material, or within such reasonably shorter period as is required (and promptly communicated by GSK to Anacor) by the relevant publication deadline, with comments on the proposed material, which GSK will consider in good faith but have no obligation to accept, or on behalf a specific statement of Iterum concern, based upon either the need to seek patent protection. In the event of concern, GSK agrees not to submit such publication or its Affiliates or Partners under this Agreement without Pfizer’s review or approval to make such presentation that contains such information until Anacor is given a reasonable period of time (unless this Agreement has been terminated not to exceed [***]) to seek patent protection for any material in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according which it believes is patentable or to resolve any other issues. This Section 9.6 shall cease to apply with respect to any Product upon the First Commercial Sale of such Product. Furthermore, with respect to any proposed abstracts, manuscripts or summaries of presentations by investigators or other Third Parties, such materials shall be subject to review under this Section 9.6 to the procedures set forth in this Section 14.3 for publication extent that GSK or presentation of Pfizer Confidential Information)Anacor (as the case may be) has the right to do so.

Publications. Pfizer shall not submit for publication In the event that Licensee or presentation, or its Affiliates desire to publish or present, present any academic, scientific information that contains the Confidential Information of AbbVie with respect to any Licensed Compound or medical publication Licensed Product or presentation disclosing the Licensed Know-How (contains Information relating to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentRGMa mechanism of action, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall Licensee will submit to Pfizer AbbVie for review any proposed academic, scientific or and medical publication or academic, scientific and medical public presentation that contains Pfizer’s Confidential Informationrelated to any Licensed Compound or Licensed Product. Such AbbVie will review will be conducted such publication or presentation for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizercontains AbbVie’s Confidential Information should be modified or deletedInformation. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written Licensee will submit written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer AbbVie no later than [ * [***] before submission for publication or presentation (or [***] in advance in the “Review Period”case of an abstract). Pfizer shall AbbVie will provide its comments with respect to such publications and presentations within [ * [***] of after its receipt of such written copy. The Review Period may be extended for an additional [ * copy (or [***] in the event Pfizer cancase of an abstract). If requested by AbbVie, within [ * ] Licensee will redact AbbVie’s Confidential Information from any such proposed publication or presentation. Notwithstanding the foregoing, the contents of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation that has been reviewed and approved by AbbVie may be re-released by Licensee without a requirement for re-approval; provided, however, that such re-release does not substantially change or expand the previously issued content. During the Term, AbbVie will not make any academic, scientific or medical publication or academic, scientific or medical public presentation related to any Licensed Compound or Licensed Product or any activities conducted pursuant to this Agreement. Any publication shall include recognition of the contributions of the other Party according to the procedures set forth in this Section 14.3 standard practice for publication assigning scientific credit, either through authorship or presentation of Pfizer Confidential Information)acknowledgement, as may be appropriate.

Publications. Pfizer The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication of results of the Research Activities hereunder. Accordingly, (i) Licensor shall not submit for publication or presentationpublish, present, or publish otherwise disclose, and shall cause its Affiliates and Third Party Providers and its and their employees and agents not to disclose any Licensor Program Know-How or material related to [*], without the prior written consent of AbbVie, and (ii) AbbVie shall not publish, present, or otherwise disclose, and shall cause its Affiliates and Third Party Providers and its and their employees and agents not to disclose any academicpre-clinical data generated prior to the Effective Date or in connection with the Research Activities, scientific SAR data, or medical compound structural information, without the prior written consent of Licensor. Additionally, except as required by Applicable Law or court order, for any proposed publication or presentation disclosing the Licensed Know-How (relating to the extent immunoproteasome by Licensor or, if such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for any pre-clinical data generated prior to the purposes of preserving Effective Date or in connection with the value of Research Activities, SAR data, or compound structural information, by AbbVie, the Licensed Technology and determining whether Party desiring to make any portion such publication shall: (a) transmit a copy of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer for review and comment to the other Party at least [*] days prior to the submission of such publication to a Third Party; (b) shall have the right postpone such publication for up to approve such proposed publications if such Pfizer’s Confidential Information relates to an additional [*] days upon request [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and is filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not of the other Party to allow the consideration of appropriate patent applications or other protection to be unreasonably withheld filed; (c) upon request of the other Party shall remove all Confidential Information of the other Party (provided that, with respect to any publication or delayedpresentation, AbbVie shall only be required to remove any pre-clinical data generated prior to the Effective Date or in connection with the Research Activities, SAR data, or compound structural information); and (d) shall consider all reasonable comments made by the other Party. Written copies Notwithstanding the foregoing to the contrary, the provisions of such proposed this Section 8.6 shall not apply with respect to any publication or presentation required made by Licensor or its Academic Collaborators under an Academic Collaboration Agreement; provided that if Licensor has rights to be submitted hereunder shall be submitted review and comment on such disclosure prior to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer public release, Licensor shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)AbbVie and shall take into consideration any reasonable comments provided by AbbVie.

Publications. Pfizer Precision shall not submit for publication publish any papers or presentationmake any oral presentations regarding results of, and other information regarding, activities pursuant to the Collaboration Program (such papers and oral presentations, including abstracts of any of the foregoing, “Publications”) if such papers or publish or presentpresentations disclose any Information relating specifically to HBV, any academic, scientific Gilead ARC Nuclease or medical publication or presentation disclosing the Licensed Know-How (Product, except as required by Applicable Law, in which case Section 7.2.2 shall apply mutatis mutandis. Notwithstanding the [***] Confidential treatment requested pursuant to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer a request for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and treatment filed separately with the Securities and Exchange Commission pursuant Commission. Omitted portions have been filed separately with the Commission. foregoing, subject to Rule 406 the obligations set forth in Sections 7.1, 7.2, and 7.3, Precision may make Publications relating specifically to the ARCUS Technology or ARCUS Assigned IP, provided that for any Publication that discloses Information relating to HBV, any Gilead ARC Nuclease or the Licensed Product, Precision shall (a) provide Gilead with a draft of such Publication at least [***] prior to submission to the Securities Act of 1933publisher, (b) remove any confidential or sensitive Information as amended. approval not requested by Gilead that Gilead reasonably deems to be unreasonably withheld of a confidential or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before sensitive nature, (c) delay the submission for publication or presentation (of such Publication for an additional [***] period to permit the “Review Period”). Pfizer shall provide its comments applicable Party under Section 6.2 to seek patent protection with respect to such publications and presentations within [ * ] of its receipt the content of such written copyInformation, and (d) consider in good faith any comments from Gilead with respect to the information contained therein pertaining to Licensed Products, Gilead ARC Nucleases or HBV. The Review Period may be extended Gilead may, in its discretion, publish any Publication; provided that, Gilead shall (i) provide Precision with a draft of such Publication at least [***] prior to submission to the publisher, (ii) remove any confidential or sensitive Information of Precision related to ARCUS Technology, ARCUS Assigned IP or ARC Nucleases generally, as requested by Precision, (iii) delay the submission for publication of such Publication for an additional [ * [***] in period to permit the event Pfizer canapplicable Party under Section 6.2 the opportunity to seek patent protection with respect to the content of such Information, within [ * ] of receipt of the written copyand (iv) give Precision a pre-publication right to review and comment upon such Publication, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum which comments shall be free to publish and present all Developed IP generated considered in good faith by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)Gilead.

Publications. Pfizer The Parties recognize the desirability of publishing and publicly disclosing the results of, and Information regarding, activities under this Agreement. Accordingly, subject to coordination through the JDC, or if the JDC has been discontinued, through designated representatives of each Party, Forest shall not submit be free to publicly disclose the results of, and information regarding, activities under this Agreement, subject to prior review by Xxxxxxx for issues of patentability and protection of its Confidential Information, in a manner consistent with Applicable Law and industry practices. In addition, if Forest intends to publish articles in scientific or medical journals or to make presentations of the results of human clinical trials involving any Licensed Compound or Licensed Product, Forest shall provide Xxxxxxx at its earliest opportunity with any proposed abstracts, manuscripts or summaries of presentations that cover such results. Xxxxxxx shall respond promptly through its designated representative, and in any event no later than [*] days after receipt of such proposed publication or presentation, or publish such shorter period as may be required by the publication. Forest agrees to allow a reasonable period (not to exceed [*] days) to permit filings for patent protection and to otherwise address issues of Confidential Information or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (related competitive harm to the extent reasonable satisfaction of Xxxxxxx. In addition, Forest will give due regard to comments furnished by Xxxxxxx and such comments shall not be unreasonably rejected. Xxxxxxx shall not, and shall cause each of its Affiliates, and its and their respective (sub)licensees not to, make any publications or public disclosures regarding any Licensed Know-How is still Pfizer’s Confidential Information) Compound or Licensed Product without IterumForest’s prior written consent. If Forest consents to Xxxxxxx making such publications, such consent not to be unreasonably withheld or delayed. During the Term, Iterum Xxxxxxx shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * provide [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not Forest a reasonable opportunity to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to comment on any such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may comments shall not be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)unreasonably rejected.

Publications. Pfizer The Parties recognize the desirability of publishing the results of Development activities under this Agreement. Accordingly, Licensee shall not submit for publication or presentation, or publish or present, any academic, be permitted to publicly disclose in scientific or medical publication journals, reference publications or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical presentations the results of Development activities under this Agreement in accordance with this Section 6.5. Prior to making any such publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes disclosure, Licensee shall provide MedImmune with drafts of preserving the value of the Licensed Technology and determining whether any portion of the such proposed publication or presentation containing Pfizer’s Confidential Information should be modified disclosure, including as applicable proposed abstracts, manuscripts or deletedsummaries of presentations. Pfizer MedImmune shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * respond promptly through its designated representative and in any event no later than [***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies after receipt of such proposed publication or presentation or such shorter period as may be required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for by the publication or presentation presentation. Licensee agrees to allow a reasonable additional period to permit filings for patent protection and to otherwise address issues of Confidential Information or related competitive harm to the reasonable satisfaction of MedImmune in a manner consistent with Applicable Law and industry practices. In addition, Licensee shall give due regard to comments furnished by MedImmune and such comments shall not be unreasonably rejected; provided, however, that if any such abstract, manuscript or summary of presentations contains any AstraZeneca Product Reference that (a) is not supported by the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended approved labeling for the AstraZeneca Product or presents an additional [ * ] in the event Pfizer can, within [ * ] of receipt unbalanced view of the written copy, demonstrate reasonable need for such extension including AstraZeneca Product considering the approved labeling for the preparation and filing AstraZeneca Product as a whole or (b) contains projections of patent applicationsthe market potential of the AstraZeneca Product, Licensee shall correct or remove such AstraZeneca Product Reference or such projections, as applicable. Iterum will comply with standard academic practice regarding authorship Notwithstanding the foregoing, subject to any copyrights or intellectual property rights of Third Parties, Licensee’s publications may include reprints of scientific or medical journal articles or reference publications and recognition of contribution of other parties regarding the AstraZeneca Product that, in any publication governed by this Section 14.3each case, including International Committee follow FDA’s “Good Reprint Practices for the Distribution of Medical Journal Editors standards regarding authorship Articles and contributionsMedical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices” guidance. For clarity, Iterum The terms of this Section 6.5 shall be free applicable to publish and present all Developed IP generated by any Sublicensee of Licensee or on behalf any of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)Affiliates.

Publications. Pfizer Neither Party nor its Affiliates shall not submit for publication publish or presentationpublicly disclose the results of any of the Research and/or Development activities conducted by either Party under this Agreement under the ADA-SCID Program, or under a Collaboration Program, or under the jointly undertaken activities of a Research Program without the prior written mutual consent of the JSC working through the JPS, except as expressly permitted in this Section 9.5 or otherwise in this Agreement. The Parties recognize that it may be useful or required to publish or presentpublicly disclose the results of Research and Development work on Programs, any academicand each Party (and its Affiliates and Sublicensees) shall be free to publish or publicly disclose such results, scientific or medical publication or presentation disclosing the Licensed Know-How (subject to the extent such Licensed Knowprior review by the JSC for patentability and protection of its Confidential Information as described in this Section 9.5. For TELETHON-How is still Pfizer’s HSR, the publication right conveyed by the preceding sentence shall apply solely to Vectors or Products prior to the exercise *** Confidential Information) without Iterum’s prior written consentTreatment Requested *** of an Option by GSK to the relevant Collaboration Program, if approved by JSC, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies The Party that desires to publish results hereunder shall provide to the JSC and JPS a copy of such proposed abstract, manuscript, or presentation no less than [***] prior to its intended submission for publication. The JSC shall respond in writing promptly and in no event later than [***] after receipt of the proposed material, with one or more of the following: (i) comments on the proposed material, which the publishing Party must consider in good faith, (ii) a specific statement of concern, based upon the need to seek patent protection, or to block publication if the JSC determines that the proposed disclosure is intellectual property that should be maintained as a trade secret to protect a Vector or Product or any Research and/or Development activities conducted under this Agreement, or (iii) an identification of the other Party’s Confidential Information that is contained in the material reviewed. In the event of concern over patent protection or whether maintaining a trade secret would be a priority, the publishing Party agrees not to submit such publication or to make such presentation that contains such information until the JSC through the JPS is given a reasonable period of time (such period of time to be no more than [***]) to seek patent protection for any material in such publication or presentation required which it believes is patentable, or to be submitted hereunder resolve any other issues or to abandon such proposed publication if the JSC reasonably determines in good faith that maintaining such information as a trade secret is a commercially-reasonable priority. Any Confidential Information of such other Party shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”)removed. Pfizer shall provide its comments Furthermore, with respect to any proposed abstracts, manuscripts or summaries of presentations by investigators or other Third Parties, such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may materials shall be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by subject to review under this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions9.5 to the extent that GSK or TELETHON-HSR (as the case may be) has the right to do so. For clarity, Iterum (a) prior to the exercise of the relevant Option to a given Collaboration Program by GSK, any proposed publication by TELETHON-HSR relating to a Collaboration Program or any Vectors shall be subject to review by the JSC in accordance with the terms of this Section 9.5, but after the expiration of the relevant Option without exercise by GSK or after the termination of a Program which then reverts to TELETHON-HSR, TELETHON-HSR shall then be free to publish and present all Developed IP generated or publicly disclose any results that relate to any Vectors or TELETHON-HSR Products in such Collaboration Program or TELETHON-HSR Development Program without any review by or on behalf of Iterum or its Affiliates or Partners the JSC under this Agreement without Pfizer’s review Section 9.5, unless such proposed disclosure or approval (unless this Agreement has been terminated in publication contains any country Joint IP or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4GSK IP, in which case Iterum JSC shall obtain Pfizer’s have the right to *** Confidential Treatment Requested *** review and approve such disclosure as stated under this Section 9.5 above, and (b) after the exercise by GSK of its Option to a Program, except as required by law or securities regulations, TELETHON-HSR shall not have the right to make any publication relating to such Collaboration Program or any Vectors or Products or GSK Development Vectors or GSK Products without the prior written consent before of the JSC, which is not to be unreasonably withheld, and GSK shall have the right to make any such publication relating to such Collaboration Program or presentation according any Vectors or GSK Development Vectors or Products or GSK Products subject to review by the JSC under this Section 9.5. Such review will not take longer than 15 Calendar Days. Notwithstanding the above, if TELETHON-HSR seeks to publish any publication regarding the ADA-SCID Program, it shall provide GSK with an advance copy of such publication and obtain GSK’s prior consent before publication, which is not to be unreasonably withheld. Notwithstanding the foregoing, to the procedures set forth in extent information regarding this Section 14.3 for publication Agreement under the ADA-SCID Program, or presentation under a Collaboration Program, or under the jointly undertaken activities of Pfizer Confidential Information)a Research Program has already been evaluated by the JPS and JSC and disclosed, TELETHON-HSR will be free to disclose the same information to the public without the consent of the other Party. For the avoidance of doubt, any substantive changes to a proposed disclosure, such as the inclusion of new data or analysis that was not previously approved by the JSC through the JPS, must be submitted to and approved by the JPS prior to its disclosure.

Publications. Pfizer The Parties recognize the desirability of publishing and publicly disclosing the results of Clinical Trials of pharmaceutical products. Accordingly, subject to coordination through designated representatives of each Party, Processa shall not submit be free to publicly disclose the results of Clinical Trials involving Compounds or Products, subject to prior review by Ocuphire for issues of patentability and protection of its Confidential Information, in a manner consistent with all Laws applicable to Processa and best industry practices. In addition, if Processa intends to publish articles in scientific or medical journals or to make presentations of the results of Clinical Trials involving Compounds or Products, Processa shall provide Ocuphire through the designated representatives of each Party at its earliest opportunity (but in any event no less than forty-five (45) days prior to intended submission or presentation) with any proposed abstracts, manuscripts or summaries of presentations that cover the results of Development of any Compound or Product. Ocuphire shall respond promptly through its designated representative, and in any event no later than thirty (30) days after receipt of such proposed publication or presentation, or publish such shorter period as may be required by the publication. If timely requested by Ocuphire, Processa agrees to allow a reasonable period (not to exceed sixty (60) days) to permit filings for patent protection and to otherwise address issues of Confidential Information or presentrelated competitive harm to the reasonable satisfaction of Ocuphire. In addition, Processa will consider in good faith any academiccomments furnished by Ocuphire to Processa during such period. Processa shall be responsible to assure that its Affiliates and licensees agree to, scientific or medical and comply with, equivalent undertakings in favor of Ocuphire. Ocuphire and its Affiliates may make any publication or presentation disclosing public disclosure of any data concerning the Licensed Know-How Compounds or Products that existed as of the Effective Date, provided that Ocuphire provides Processa at least thirty (30) days (or such shorter period as may be required by the publication) to review such publication or public disclosure, allows a reasonable period (not to exceed sixty (60) days) to permit filings for patent protection and to otherwise address issues of Confidential Information or related competitive harm to the extent reasonable satisfaction of Processa, and reasonably considers any timely comments provided by Processa with respect to such Licensed Know-How is still Pfizer’s Confidential Information) publication or public disclosure. Ocuphire shall not, and shall cause each of its Affiliates, licensees, and sublicensees not to, make any other publications or public disclosures regarding the Compounds or Products without IterumProcessa’s prior written consent. If Processa consents to Ocuphire making such publications, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer Ocuphire shall provide its comments with respect Processa a reasonable opportunity to comment on any such publications and presentations within [ * ] of its receipt of such written copycomments shall not be unreasonably rejected. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply All publications involving Compounds or Products shall include appropriate acknowledgement consistent with standard academic scientific practice regarding authorship of scientific publications and recognition any contributions of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according each Party to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)results being publicly disclosed.

Publications. Pfizer Neither PARTY shall not submit for publication or presentation, or publish or presentpresent the results of any research, development or any academicother information relating to any PRODUCT without securing the prior approval of the DEVELOPMENT COMMITTEE, scientific or including but not limited to, data presented with respect to any PRODUCT at key medical publication meetings, releases developed by either PARTY in conjunction with key medical institutions, and other releases used in support of brand positioning and educational campaigns related to any PRODUCT. The PARTY desiring to publish any abstract, manuscript or presentation disclosing the Licensed Know-How (with respect to any PRODUCT shall submit such document for review to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentDEVELOPMENT COMMITTEE sufficiently in advance of the proposed date of submission of the publication so that, where reasonable under the circumstances, such consent not DEVELOPMENT COMMITTEE has at least forty-five (45) days to review the proposed publication. The DEVELOPMENT COMMITTEE will use its best efforts to expedite the review of any publications that are time sensitive. Either PARTY shall be unreasonably withheld or delayed. During entitled to use the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted data provided by the other hereunder for the purposes of preserving creating marketing and promotional material for use by XXXXXX in the value TERRITORY and by MEDIMMUNE outside of the Licensed Technology and determining whether TERRITORY; provided, however, that, any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder material shall be submitted to Pfizer no later than [ * ] before submission the DEVELOPMENT COMMITTEE for publication review and approval prior to its use or presentation (the “Review Period”)publication. Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth Notwithstanding anything in this Section 14.3 6.10 to the contrary, neither PARTY shall be required to seek the approval of the other PARTY for the publication of the results of research, development or any other information relating to any PRODUCTS that has been submitted to any THIRD PARTY for publication on or presentation prior to the EFFECTIVE DATE; provided, however, that XXXXXX shall provide MEDIMMUNE with copies of Pfizer Confidential Information)all such publications (or pending publications) within forty-five (45) days after the EFFECTIVE DATE. Both PARTIES shall maintain the confidentiality of the results and data provided to the other PARTY hereunder in accordance with Section 8.5.

Publications. Pfizer shall During the Term and the term of the License Agreement, Altus will not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing publications regarding the Licensed Know-How Product (to including the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = ***Certain confidential information contained in on this document, marked by brackets, page has been omitted and filed separately with the Securities and Exchange Commission pursuant Commission. Confidential treatment has been requested with respect to Rule 406 the omitted portions. Development Results) without the prior written consent of the Securities Act of 1933, as amendedZogenix. approval not to be unreasonably withheld or delayed. Written copies of such Any proposed publication or presentation required by Zogenix regarding the Licensed Product in the Territory (including the Development Results) shall comply with this Section 7.5. At least [***] before a manuscript is to be submitted hereunder shall be submitted to Pfizer no later than [ * a publisher, Zogenix will provide Altus with a copy of the manuscript. If Zogenix wishes to make an oral or visual presentation at any conference, it will provide Altus with a summary of such presentation, unless such disclosed information has previously been reviewed by Altus, at least [***] before submission for publication such oral or visual presentation (the “Review Period”)and, if an abstract is to be published, [***] before such abstract is to be submitted. Pfizer Any oral or visual presentation, including any question period, shall provide its comments with respect not include any Confidential Information belonging to Altus unless Altus agrees in writing to such publications and presentations within [ * ] of its receipt inclusion in advance of such written copyoral presentation. The Review Period may be extended for an additional [ * ] in Altus will review the event Pfizer canmanuscript, abstract, text or any other material provided to it to determine whether patentable subject matter or valuable trade secrets of Altus are disclosed and to assess the accuracy of the technical content therein. Altus will notify Zogenix within [ * [***] of receipt of the written copyproposed publication if Altus, demonstrate reasonable need in good faith, determines that patentable subject matter or valuable trade secrets of Altus are or may be disclosed, or if Altus, in good faith, believes Confidential Information of Altus is or may be disclosed. If it is determined by Altus that patent applications should be filed in advance of the proposed publication, Zogenix shall delay its publication or presentation for such extension including a period not to exceed [***] from Altus’ receipt of the proposed publication or presentation to allow time for the preparation and filing of patent applicationsapplications covering patentable subject matter. Iterum will comply with standard academic practice regarding authorship If it is determined in good faith by Altus that Confidential Information of scientific publications and recognition of contribution of other parties Altus is being disclosed, the Parties shall consult in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free good faith to publish and present all Developed IP generated by or arrive at an agreement on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant mutually acceptable modifications to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such the proposed publication or presentation according to avoid such disclosure. Any publications (whether written or oral), where consistent with customary academic practice, shall acknowledge Altus as the procedures set forth in this Section 14.3 for publication or presentation developer and licensor of Pfizer Confidential Information)the Altus Technology and the Altus Product Technology.

Publications. Pfizer shall not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer Verastem shall have the right to approve publicly present or publish any Clinical Trial data, non-clinical data or any associated results or conclusions generated pursuant to this Agreement (each such proposed publications if presentation or publication, a “Publication”), provided that (a) such Pfizer’s Publication shall not include any Confidential Information relates of Licensee without Licensee’s prior written consent and (b) Verastem shall notify Licensee at least [* * *] days prior to [ * ]making such Publication and permit Licensee to request a delay in such Publication so that Licensee may file for patent protection as necessary. Licensee shall not have the right to issue any Publication except with the prior written approval of Verastem, such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld withheld, conditioned or delayed, and in accordance with Verastem's Global Strategy. Written copies If Licensee desires to publicly present or publish a Publication in accordance with the foregoing sentence, then Licensee shall provide Verastem (including the Alliance Manager and all Verastem members of the JCC) with a copy of such proposed publication Publication at least [* * *] days prior to the earlier of its presentation or presentation required intended submission for publication, or if Licensee has fewer than [* * *] days before submitting such proposed Publication for the reasons of authors, Licensee shall provide Verastem (including the Alliance Manager and all Verastem members of the JCC) with a copy of such proposed Publication as soon as reasonably practicable. Licensee agrees that it will not submit or present any Publication until Verastem has approved such Publication in writing. Licensee shall incorporate any reasonable written comments received from Verastem, including (a) the deletion of any Confidential Information of Verastem that Verastem identifies for deletion in Verastem’s written comments, and (b) the deletion of any Clinical Trial data, results, conclusions or other related information which Verastem determines, in its sole discretion, to be submitted hereunder conflict with Verastem’s Global Strategy with respect to the Licensed Product. If permitted to publish or present any Publication pursuant to this Section 8.4 Licensee shall be submitted to Pfizer no later than [ * ] before provide Verastem a copy of the Publication at the time of the submission for publication or presentation (presentation. Licensee agrees to acknowledge the “Review Period”)contributions of Verastem, and the employees of Verastem, in all Publications as scientifically appropriate. Pfizer Licensee shall provide require its comments with respect Affiliates, Sublicensees and Subcontractors to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship the obligations of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.38.4 as if they were Licensee, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 liable for publication or presentation of Pfizer Confidential Information)their non-compliance.

Publications. Pfizer shall not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer BMS shall have the right to approve such proposed publications publish manuscripts, abstracts, presentations or other articles in scientific journals or at scientific conferences relating to any Licensed Target, Licensed Compound or Licensed Product without obtaining the prior written consent of Avidity; provided, however, that (a) if a Avidity employee is also named as an author or (b) if such Pfizer’s Confidential Information relates manuscripts, abstracts, presentations or other articles contain information relating to [ * ]Avidity AOC Platform Technology, then Avidity shall have the right to review and comment upon each such [ * ] = Certain confidential information contained manuscript, abstract, presentation or other article in this documentwhich and BMS shall consider such comments in good faith. Avidity may not publish manuscripts, marked by bracketsabstracts, has been omitted and filed separately with presentations or other articles in scientific journals or at scientific conferences related to any Licensed Target, Licensed Compound or Licensed Product, without the Securities and Exchange Commission prior written consent of BMS. If BMS desires to make a publication pursuant to Rule 406 this Section 8.9 for which Avidity has the right to comment, BMS shall provide a copy of the Securities Act of 1933proposed publication (including abstracts, as amended. approval not or presentation to be unreasonably withheld a journal, editor, meeting, seminar or delayed. Written copies other third party) to Avidity for at least [***] prior to submission of such proposed manuscript for publication; the object being to prevent either the endangerment of applications for the protection of property rights by premature publications detrimental to their novelty or the disclosure of Confidential Information. If, during the [***] specified above Avidity notifies BMS that a proposed publication or presentation required contains patentable subject matter directed to be submitted hereunder shall be submitted Avidity Platform Inventions that requires protection, Avidity may by written notice delay the publication for a period of time not to Pfizer no later than [ * exceed [***] before submission for publication or presentation (from the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt date of such written copy. The Review Period notice to seek appropriate patent protection for any subject matter in such publication that it reasonably believes may be extended for an additional [ * ] patentable. BMS shall delete from the proposed publication prior to submission all Confidential Information of Avidity that Avidity identifies in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation good faith and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall requests to be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)deleted.

Publications. Pfizer Neither Party or its Affiliates shall publish or publicly disclose the results of any of the research and/or development activities conducted under the Research Program or under any Early Development Program, without the prior written consent of the other Party, except that after the end of the Research Term, the foregoing shall not submit apply to ChemoCentryx for publication or presentationresults that do not relate to any Collaboration Compounds, or to GSK for EXECUTION VERSION results that relate directly to any of the Product Candidates or Licensed Products. The Parties recognize that it may be useful or required to publish or presentpublicly disclose the results of development work on Licensed Products, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How and GSK (to the extent such Licensed Know-How is still Pfizer’s Confidential Informationand its Affiliates and Sublicensees) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish or publicly disclose such results, subject to the prior review by ChemoCentryx for patentability and present all Developed IP generated protection of its Confidential Information. GSK shall provide to ChemoCentryx at GSK’s earliest practical opportunity any proposed abstracts, manuscripts or summaries of presentations which cover the results of clinical development of any Licensed Product, for review and comment as to matters relating to its patents and Confidential Information. ChemoCentryx shall respond in writing promptly and in no event later than thirty (30) days after receipt of the proposed material, or within such reasonably shorter period as is required (and promptly communicated by GSK to ChemoCentryx) by the relevant publication deadline, with either approval of the proposed material or on behalf a specific statement of Iterum concern, based upon either the need to seek patent protection or its Affiliates concern regarding competitive disadvantage arising from the proposal. In the event of concern, GSK agrees not to submit such publication or Partners under this Agreement without Pfizer’s review or approval to make such presentation that contains such information until ChemoCentryx is given a reasonable period of time (unless this Agreement has been terminated not to exceed sixty (60) days) to seek patent protection for any material in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according which it believes is patentable or to resolve any other issues. This Section 9.6 shall cease to apply with respect to any Licensed Product upon the commercial launch of such Licensed Product. Furthermore, with respect to any proposed abstracts, manuscripts or summaries of presentations by investigators or other Third Parties, such materials shall be subject to review under this Section 9.6 to the procedures set forth in this Section 14.3 for publication extent that GSK or presentation of Pfizer Confidential Information)ChemoCentryx (as the case may be) has the right to do so.

Publications. Pfizer The Parties, through the JDC, shall develop policies and procedures (the “Publication Policies”) for any publication with respect to the results of Clinical Studies and Post-Approval Marketing Studies for a Product in the Field in the Territory, including disclosure applicable to clinical trial registries, which policies and procedures shall be consistent with the Parties’ respective policies and procedures for publication and disclosure of the results of human clinical trials consistently applied. All abstracts, manuscripts and presentations (including information to be presented verbally) that disclose results of Clinical Studies or Post-Approval Marketing Studies for a Product in the Field in the Territory shall be reviewed and approved by the JDC in accordance with the Publication Policies. Notwithstanding the foregoing, each Party shall provide to the other Party (through the JDC) the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) in the Territory that relate to any Development activities or otherwise with respect to the Product for use in the Field in the Territory, at least […***…] prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such […***…] period, not to submit such abstract or manuscript for publication or presentation, or publish or present, to make such presentation until the other Party is given up to […***…] from the date of such written request to seek appropriate patent protection for any academic, scientific or medical material in such publication or presentation disclosing that it reasonably believes may be patentable. Once an abstract, manuscript or presentation has been reviewed and approved by the Licensed Know-How (JDC, the exact same abstract, manuscript or presentation does not have to be provided again to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer other Party for review any proposed academic, scientific for a later submission for publication; provided that once the abstract or medical manuscript is accepted for publication or public the presentation that contains Pfizer’s Confidential Information. Such review will be conducted for is finalized, the purposes of preserving submitting Party shall provide the value other Party with a copy of the Licensed Technology and determining whether any portion final version of the proposed publication such abstract, manuscript or presentation containing Pfizer’s Confidential Information should be modified or deletedpresentation. Pfizer Each Party also shall have the right to approve such proposed publications if such Pfizer’s require that any of its Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained (but not the results of the Clinical Studies or Post-Approval Marketing Studies for a Product in this document, marked by brackets, has the Field in the Territory that have been omitted and filed separately with the Securities and Exchange Commission approved for disclosure pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of Publication Policies) that is disclosed in any such proposed publication or presentation required be deleted prior to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary standards. For the avoidance of doubt and notwithstanding the foregoing, this Section10.3.2 shall not limit or restrict Sucampo’s ability to publish or present publicly available information for the Product outside of the Territory or, for Other Formulation(s) or Dosage(s) or Other Indications within the Territory (except to the “Review Period”). Pfizer shall provide extent that Xxxxxx has exercised its comments right of refusal for a particular Other Formulation or Dosage or Other *Confidential Treatment Requested Indication and the Parties have reached written agreement with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] the same under Section 5.2) or otherwise, provided that in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which each case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer does not contain Gloria’s Confidential Information).

Publications. Pfizer Neither Party shall not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing present the Licensed Knowresults of studies carried out during the Collaborative Research Period and the BMS Independent Activity Period (including results of studies carried out with Non-How (to the extent such Licensed Know-How is still Pfizer’s Confidential InformationLXR Modulators) without Iterum’s the opportunity for prior written consentreview by the other Party; provided, such consent not however, that BMS may publish or present the results of studies with respect to be unreasonably withheld or delayedCollaboration Compounds that have received approval as an ECN without prior review by Exelixis. During Subject to Section 9.3, each Party agrees to provide the Term, Iterum shall submit other Party the opportunity to Pfizer for review any proposed academic, scientific or medical publication or public presentation that disclosure which contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value Information of the Licensed Technology other Party and determining whether would or may constitute an oral, written or electronic public disclosure if made (including the full content of proposed abstracts, manuscripts or presentations) which relate to [ * ], or which otherwise may [ * ], at least [ * ] prior to its intended submission for publication and agrees, upon request, not to submit any portion such abstract or manuscript for publication until the other Party is given a reasonable period of the proposed time to secure patent protection for any material in such publication which it believes to be patentable. Both Parties understand that a reasonable commercial strategy may require delay of publication of information or presentation containing Pfizer’s Confidential Information should be modified or deletedfiling of patent applications. Pfizer The Parties agree to review and consider delay of publication and filing of patent applications under certain circumstances. The JRC shall review such requests and recommend subsequent action. Neither Party shall have the right to approve such proposed publications if such Pfizer’s publish or present Confidential Information relates of the other Party which is subject to [ * ], such Section 9.1. Nothing contained in this Section 9.6 shall prohibit the inclusion of Confidential Information of the non-filing Party [ * ] = Certain confidential information contained in this documentCERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, marked by bracketsMARKED BY BRACKETS, has been omitted IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. necessary for a patent application, provided the non-filing Party is given a reasonable opportunity to review the extent and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not necessity for its Confidential Information to be unreasonably withheld or delayed. Written copies included prior to submission of such proposed patent application. Any disputes between the Parties regarding delaying a publication or presentation required to be submitted hereunder permit the filing of a patent application shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according referred to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)JRC.

Publications. Pfizer Except as provided in this Agreement, neither Party or its Affiliates shall publish or publicly disclose the results of any of the research and/or development activities conducted under this Agreement, without the prior written consent of the other Party, except that after the expiration of all Options, the foregoing shall not submit apply to Anacor for publication or presentationresults that relate to any Anacor Development Compounds, or to GSK for results that relate directly to any GSK Development Compounds. The Parties recognize that it may be useful or required to publish or presentpublicly disclose the results of development work on Products, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How and GSK (to the extent such Licensed Know-How is still Pfizer’s Confidential Informationand its Affiliates and Sublicensees) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum only shall be free to publish or publicly disclose such results, subject to the prior review by Anacor for patentability and present all Developed IP generated protection of its Confidential Information. GSK shall provide to Anacor at GSK’s earliest practical opportunity any proposed abstracts, manuscripts or summaries of presentations which cover the results of clinical development of any Product, for review and comment as to matters relating to its patents and Confidential Information. Anacor shall respond in writing promptly and in no event later than [***] after receipt of the proposed material, or within such reasonably shorter period as is required (and promptly communicated by GSK to Anacor) by the relevant publication deadline, with [***] THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION. comments on the proposed material, which GSK will consider in good faith but have no obligation to accept, or on behalf a specific statement of Iterum concern, based upon either the need to seek patent protection. In the event of concern, GSK agrees not to submit such publication or its Affiliates or Partners under this Agreement without Pfizer’s review or approval to make such presentation that contains such information until Anacor is given a reasonable period of time (unless this Agreement has been terminated not to exceed [***]) to seek patent protection for any material in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according which it believes is patentable or to resolve any other issues. This Section 9.6 shall cease to apply with respect to any Product upon the First Commercial Sale of such Product. Furthermore, with respect to any proposed abstracts, manuscripts or summaries of presentations by investigators or other Third Parties, such materials shall be subject to review under this Section 9.6 to the procedures set forth in this Section 14.3 for publication extent that GSK or presentation of Pfizer Confidential Information)Anacor (as the case may be) has the right to do so.

Publications. Pfizer 9.1.1. Except as otherwise set forth in this this Agreement, (a) MKDG shall not submit for publication or presentationhave the sole right to publish, or make any other presentation or disclosure of, any data, material, Results (other than Results relating to C4T Foreground IP or C4T Platform IP) or other information generated under or in connection with the performance of the Research Collaboration, subject to the terms and conditions of this Section 9.1, and (b) C4T (and its Affiliates) shall have no right to publish or present, publicly disclose any academic, scientific such Results or medical publication or presentation disclosing the Licensed Know-How (information generated pursuant to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayedactivities performed under this Agreement unless otherwise approved by MKDG in writing. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer C4T shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such review any proposed publication or disclosure, presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation abstract or portion thereof by MKDG that contains any Results generated under the Work Plan during the Collaboration Phase (collectively, the “Review PeriodCollaboration Information”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] ) or that includes Confidential Information of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. C4T. For clarity, Iterum C4T shall be free not have the right to publish and present all Developed IP generated review any proposed publication or other disclosure, presentation or abstract by MKDG to the extent pertaining to activities conducted during the MKDG Phase, including to the extent setting forth the results of any clinical trial of a Product conducted by or on behalf of Iterum MKDG or its Affiliates Related Parties, so long as such proposed publication or Partners under this Agreement without Pfizer’s other disclosure, presentation or abstract does not include any Collaboration Information (other than the chemical structure of the Compound being evaluated in such clinical trial) or Confidential Information of C4T. Before any such publication, disclosure, presentation or abstract is submitted or an oral presentation is made, MKDG shall deliver to C4T a copy of any such publication, disclosure, presentation or abstract at least [***] prior to submission or presentation for review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 9.1.2. For clarity, nothing in this Agreement, including this Section 9.1, shall prevent C4T from filing and prosecuting patent applications relating to C4T Platform Know-How and C4T Foreground Know-How. 9.1.2. C4T shall have the right to request (a) the removal of its Confidential Information from any such publication, disclosure, presentation or abstract by Iterum pursuant to Section 13.4MKDG, or (b) a reasonable delay in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according in order to the procedures set forth in this Section 14.3 for publication protect patentable information. If C4T requests that its Confidential Information be removed from any such publication, disclosure, presentation or abstract, MKDG shall delete such Confidential Information. If C4T requests such a delay, MKDG shall delay submission or presentation for a period of Pfizer Confidential Information).[***] after its provision of the copy of the publication, disclosure, presentation or abstract to enable patent

Publications. Pfizer The Parties, through the JDC, shall not submit develop policies and procedures (the “Publication Policies”) for any publication with respect to the results of Clinical Studies and Post-Approval Marketing Studies for a Product in the Territory, including disclosure applicable to clinical trial registries, which policies and procedures shall be consistent with the Parties’ respective policies and procedures for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and is filed separately with the Securities and Exchange Commission pursuant to Rule 406 24b-2 of the Securities Exchange Act of 19331934, as amended. approval disclosure of the results of human clinical trials, with disputes to be resolved in favor of the polity that provides for the broadest disclosure of such results. All abstracts, manuscripts and presentations (including information to be presented verbally) that disclose results of Clinical Studies or Post-Approval Marketing Studies for a Product shall be reviewed and approved by the JDC in accordance with the Publication Policies. Notwithstanding the foregoing, each Party shall provide to the other Party (through the JDC) the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) that relate to any Development activities or otherwise with respect to the Product, at least thirty (30) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such thirty (30)-day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to sixty (60) days from the date of such written request to seek appropriate Patent protection for any material in such publication or presentation that it reasonably believes may be unreasonably withheld patentable. Once an abstract, manuscript or delayedpresentation has been reviewed and approved by the JDC, the same abstract, manuscript or presentation does not have to be provided again to the other Party for review for a later submission for publication. Written copies Each Party also shall have the right to require that any of its Confidential Information (but not the results of the Clinical Studies or Post-Approval Marketing Studies for a Product that have been approved for disclosure pursuant to the Publication Policies) that is disclosed in any such proposed publication or presentation required be deleted prior to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for such publication or presentation. In any permitted publication or presentation (by a party, the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of other Party’s contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish duly recognized, and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated co-authorship shall be determined in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)accordance with customary standards.

Publications. Pfizer The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party (in such capacity the “Publishing Party”) agrees that, except as required by Applicable Laws, it shall not submit for publication or presentation, or publish or present, or permit to be published or presented, any academicresults of the Development, scientific Manufacture, use or medical publication or presentation disclosing ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Commercialization of a Licensed Know-How (Product to the extent such results refer to, derive from or otherwise relate to the Licensed KnowIntellectual Property (the “Covered Results”), without the prior review by and approval of the other Party (in such capacity, the “Non-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentDisclosing Party”), such consent which approval shall not to be unreasonably withheld withheld; provided that it shall not be deemed unreasonable for ImmunoGen to withhold its consent to any request by CytomX to publish or delayeddisseminate Covered Results prior to the publication or dissemination of such Covered Results by ImmunoGen. During the Term, Iterum The Publishing Party shall submit to Pfizer the Non-Disclosing Party for review and approval any proposed academic, scientific or and medical publication or public presentation that which contains PfizerCovered Results or otherwise contains the Non-Disclosing Party’s Confidential Information; provided that the foregoing requirement shall apply to ImmunoGen only to the extent any such proposed publication or presentation would refer to, describe or otherwise disclose Confidential Information of CytomX (including, without limitation, any non-public Licensed Intellectual Property). Such In addition, each Party shall submit to the other Party for review and approval any proposed publication or public presentation relating to data generated under the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology Intellectual Property and determining whether any portion of the proposed publication or presentation containing Pfizerthe Non-Disclosing Party’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * [***] before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * [***] of after its receipt of such written copy, and the Publishing Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional [ * [***] in the event Pfizer the Non-Disclosing Party can, within [ * [***] of receipt of the written copy, demonstrate reasonable need for such extension extension, including for the preparation and filing of patent applications. Iterum The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)6.3.2.

Publications. Pfizer shall not submit Actinium acknowledge that it is Site's policy that the results of the Study must be publishable and the Investigator and others employed by Site or who are engaged in the Study be permitted to present at symposia, national or regional professional meetings and to publish in journals, theses or dissertations or otherwise in their sole discretion, the methods and results of the Study. The parties recognize that because this is a multi-center Study, there is a need for a coordinated approach to any publication or public disclosure of the data or results of this Study. To that end, there will be no publication or public disclosure of such data or results by the Site or Investigator until a multi-center publication is submitted for publication or presentationpresentation by Actinium, or its designee. However, if no multi-site publication is submitted by Actinium or its designee within twelve (12) months of the completion termination, or abandonment of the Study from all sites, the Site and the Investigator shall be free to publish for non-commercial purposes the Study results from there Site as follows. If the Site or the Investigator wishes to publish or present, publicly disclose Study and data or results the Site will submit any academic, scientific proposed manuscript or medical publication to Actinium for comment at least thirty (30) days prior to its submission for publication or presentation disclosing other disclosure. The Site will review and consider in good faith comments received from Actinium during such thirty (30) day period. If requested to do so by Actinium, Site agrees to remove confidential information provided by Actinium prior to submitting the Licensed Know-How manuscript or publication, excluding Study data / results or any other information that may be required by the publishing source. Actinium will make every reasonable attempt to notify the Site within said thirty (to the extent such Licensed Know-How is still Pfizer’s Confidential Information30) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes days of preserving the value of the Licensed Technology and determining whether any portion receipt of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deletedwhether it is desirable to file a patent application on any inventions contained in the proposed publication. Pfizer In the event Actinium decides to pursue patent protection, Actinium shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed defer publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in thirty (30) days to permit the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of any desired patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)application.

Publications. Pfizer shall not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum each Party shall submit to Pfizer the other Party (the “Non-Disclosing Party”) for review and approval any proposed academic, scientific or and medical publication or public presentation that which contains Pfizerthe Non-Disclosing Party’s Confidential Information. Such In addition, each Party shall submit to the other Party for review and approval any proposed publication or public presentation relating to data generated under the Research Program, provided that Pfizer shall not be required to submit any proposed publication or public presentation to CytomX for review and approval pursuant to this sentence to the extent such publication or presentation relates to any Research Project Target for which Pfizer has exercised its Option pursuant to this Agreement and to the extent consistent with Pfizer’s normal and customary publication practices. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology Intellectual Property and PDC Developed IP and the rights granted to Pfizer hereunder and determining whether any portion of the proposed publication or presentation containing Pfizerthe Non-Disclosing Party’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve Written copies of such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = ***Certain confidential information contained in this document, marked by brackets, herein has been omitted and filed separately with the Securities and Exchange Commission pursuant Commission. Confidential treatment has been requested with respect to Rule 406 of the Securities Act of 1933, as amendedomitted portions. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * ] thirty (30) days before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * ] of twenty (20) days after its receipt of such written copy, and the other Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional [ * ] sixty (60) days in the event Pfizer the Non-Disclosing Party can, within [ * ] fifteen (15) days of receipt of the written copy, demonstrate reasonable need for such extension extension, including for the preparation and filing of patent applications. Iterum CytomX and Pfizer will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)7.3.2.

Publications. Pfizer shall not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review The Project will be conducted for the purposes of preserving the value form part of the Licensed Technology and determining whether any portion actual carrying out of a primary charitable purpose of the proposed publication University; that is, the advancement of education through teaching and research. In accordance with normal academic practice, all employees, students, agents or presentation containing Pfizer’s Confidential Information should appointees of the University (including the Student and any others who work on the Project) shall be modified permitted, following the procedures laid down in Clause 6.3, to publish Arising Intellectual Property or deleteddiscuss Arising Intellectual Property in internal seminars, and to give instructions within the University on questions related to such work. Pfizer shall have the right to approve such All proposed publications if such Pfizer’s Confidential Information relates to [ * ](including, such [ * ] = Certain but not limited to, academic publications, patent applications and non-confidential information contained in this documentpresentations), marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted in writing to Pfizer no later than [ * ] the other of the Partner Organisation and the University for review at least thirty (30) days before submission for publication or presentation (before presentation, as the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copycase may be. The Review Period reviewing Party may be extended for require the deletion from the publication of any Background Intellectual Property of the reviewing Party, or an additional [ * ] amendment to the publication through which commercially sensitive Background Intellectual Property is disguised to the satisfaction of the reviewing Party. The reviewing Party may also request the delay of the publication if in the event Pfizer can, within [ * ] reviewing Party’s opinion the delay is necessary in order to seek patent or similar protection to Arising Intellectual Property owned by the reviewing Party. Any delay imposed on publication shall not last longer than is reasonably necessary for the reviewing Party to obtain the required protection; and shall not exceed six (6) months from the date of receipt of the written copyproposed publication by the reviewing Party. Notification of the requirement for delay in publication must be received by the publishing Party within thirty (30) days after receipt of the proposed publication by the reviewing Party, demonstrate reasonable need for such extension including for failing which the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum publishing Party shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement assume that the reviewing Party has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according no objection to the procedures set forth proposed publication. Each Party agrees that any publication in this Section 14.3 for publication or presentation an academic journal shall give due acknowledgement to the financial and/or intellectual contribution of Pfizer Confidential Information)the others in accordance with standard scientific practice. Clause 6 does not apply to the submission of the Thesis, which is governed by Clause 7.

Publications. Pfizer Notwithstanding anything to the contrary in this Agreement, (a) prior to Alnylam’s exercise of the Alnylam Commercialization Option for a particular Product pursuant to Section 4.3 and after Alnylam declines to exercise the Alnylam Commercialization Option for such Product, Dicerna shall not submit have the sole right to publish the results of the Development activities with respect to such Product, subject to the process described below; and (b) after Alnylam’s exercise of the Alnylam Commercialization Option for a particular Product, the Parties shall, through JCC, coordinate and determine publication of the results of the Development activities with respect to such Product. In the event that Dicerna desires to make any publication or public presentation relating to a Product under clause (a) above and such publication or presentation contains Alnylam’s Confidential Information, Dicerna shall deliver to Alnylam a copy of the proposed written publication or presentation at least [* * *] days prior to || submission for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer Alnylam shall have the right (i) to approve such proposed publications if such Pfizer’s Confidential Information relates propose modifications to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation for patent reasons, trade secret reasons or business reasons, which proposals Dicerna may accept or reject in its discretion (except that Dicerna shall be required to be submitted hereunder shall be submitted remove any Confidential Information of Alnylam at Alnylam’s request), and (ii) to Pfizer no later than [ * ] before submission for request a reasonable delay in publication or presentation in order to protect patentable information in accordance with Article 8. If Alnylam requests a delay pursuant to clause (the “Review Period”ii), Dicerna shall delay submission or presentation for up to a [* * *] additional days to enable Alnylam to file patent applications protecting Alnylam’s rights in such information in accordance with Article 8. Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] In any scientific publication in the event Pfizer canscientific literature (journal article, within [ * ] of receipt of book chapter, poster) referencing data created or generated by Alnylam related to the written copyProducts, demonstrate reasonable need for such extension including Dicerna shall endeavor to include appropriate acknowledgements, consistent with the Recommendations for the preparation Conduct, Reporting, Editing, and filing Publication of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties Scholarly Work in any publication governed Medical Journals published by this Section 14.3, including the International Committee of Medical Journal Editors standards regarding authorship Editors, of the related roles and contributions. For clarity, Iterum shall be free to publish contributions of Alnylam and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)entities’ respective individual involved scientists.

Publications. Pfizer Dong-A may develop policies and procedures (the “Publication Policies”) for any publication with respect to the results of Clinical Trials for a Licensed Product in the applicable Field in the Territory, including disclosure applicable to clinical trial registries, which policies and procedures shall be consistent with the Dong-A’s own policies and procedures for publication and disclosure of the results of human clinical trials consistently applied. All abstracts, manuscripts and presentations (including information to be presented verbally) that disclose results of Clinical Trials for a Licensed Product in the applicable Field in the Territory shall be reviewed and approved by Dong-A consistent with any Publication Policies of Dong-A. In addition to and not in lieu or limitation of the foregoing, NeuroBo shall provide to Dong-A (through the JDC) the opportunity to review each of NeuroBo’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) in the Territory that relate to any Development activities or otherwise with respect to the Licensed Products for use in the applicable Field in the Territory, at least [**] days prior to its intended presentation or submission for publication, and NeuroBo agrees, upon written request from Dong-A given within such [**] day period, not to submit such abstract or manuscript for publication or presentation, or publish or present, to make such presentation until Dong-A is given up to [**] days from the date of such written request to seek appropriate patent protection for any academic, scientific or medical material in such publication or presentation disclosing that it reasonably believes may be patentable. Once an abstract, manuscript or presentation has been reviewed and approved by Dxxx-X, the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentexact same abstract, such consent manuscript or presentation does not have to be unreasonably withheld or delayed. During the Term, Iterum shall submit provided again to Pfizer Dong-A for review any proposed academic, scientific for a later submission for publication; provided that once the abstract or medical manuscript is accepted for publication or public the presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value is finalized, NeuroBo shall provide Dong-A with a copy of the Licensed Technology and determining whether any portion final version of the proposed publication such abstract, manuscript or presentation containing Pfizer’s Confidential Information should be modified or deletedpresentation. Pfizer Dong-A also shall have the right to approve such proposed publications if such Pfizer’s require that any of its Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained (but not the results of the Clinical Studies for a Licensed Product in this document, marked by brackets, has the applicable Field in the Territory that have been omitted and filed separately with the Securities and Exchange Commission approved for disclosure pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of Publication Policies) that is disclosed in any such proposed publication or presentation required be deleted prior to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for such publication or presentation. In any permitted publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer canby NeuroBo, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of Dong-A’s contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish duly recognized, and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated co-authorship shall be determined in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)accordance with customary standards.

Publications. Pfizer shall not submit for publication Approved Investigator may publish or otherwise publicly disclose the results of the Study, which public disclosures may be in the form of abstract, manuscript, reports, or presentation. However, in the case of an approved clinical study under this Agreement, NCI Collaborator will have forty-five (45) days to review proposed xxxxxxxxxxxxxx.xxx results and reports submissions and proposed manuscripts for publication, and seven (7) business days to review proposed abstracts or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (presentations to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation assure that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing PfizerNCI Collaborator’s Confidential Information should is protected, except when a shortened time period under a court order or the Freedom of Information Act pertains. NCI Collaborator may request in writing that a proposed manuscript, resulted from an approved clinical or non-clinical Study outlined in Attachment A be modified delayed for up to sixty (60) additional days as necessary to file, or deletedrequest Approved Investigator, and/or Institution to file a patent application or other action to protect NCI Collaborator’s intellectual property interests. Pfizer Any proposed press release by Institution that references or relies upon the Study under this Agreement shall be submitted to NCI and NCI Collaborator for review and comment at least five (5) business days before publication. Manuscripts to be submitted for publication and proposed abstracts or presentations by Approved Investigators will be sent to NCI’s Regulatory Affairs Branch at NCI CTEP Publications for forwarding to NCI Collaborator for review as soon as they are received and in compliance with the timelines outlined above. In all oral presentations or written publications concerning the Study, Institution agrees to acknowledge NCI, the NCI Formulary program and NCI Collaborator’s contribution of the Formulary Agent(s) unless requested otherwise. Data. Institution agrees and Approved Investigator knowledges that all de-identified data and results of the Study generated under this Agreement (“Study Data”) will be provided to or made available for access by NCI Collaborator including all public disclosures as described in Article 4. Further, Institution on behalf of Approved Investigator agrees to keep Study Data confidential until published and agrees that NCI Collaborator will have the right to approve use any and all such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted Study Data for any lawful purposes including regulatory filing and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply In the case of an approved clinical Study under this Agreement, Institution further agrees to make sure the informed consent form includes language providing the NCI Collaborator with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3access to all Study Data, including International Committee of Medical Journal Editors standards regarding authorship raw data and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 report forms for publication or presentation of Pfizer Confidential Information)regulatory purposes.

Publications. Pfizer shall not submit for Each Party recognizes that the publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (of papers regarding results of and other information regarding activities under this Agreement may be beneficial to the extent both Parties; provided such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not publications are subject to be unreasonably withheld or delayed. During the Term, Iterum shall submit reasonable controls to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s protect Confidential Information. Such review will be conducted for In particular, it is the purposes of preserving the value intent of the Licensed Technology and determining whether Parties to maintain the confidentiality of any portion Confidential Information included in any patent application until such Patent application has been filed. Accordingly, (a) except as set in the attached Exhibit G, which Exhibit G sets forth all draft papers pending publication as of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer Effective Date, Licensee shall have the right to approve review and approve, and (b) POZEN shall have the right to review and comment on, any paper proposed for publication by the other Party or any of its Affiliates (including any oral presentation or abstract) that contains clinical data or pertains to results of pre-approval clinical studies, Phase 4 Trials, THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Post-Approval Commitments or other clinical studies with respect to the Licensed Products or includes other data generated under this Agreement (each a “Publication”). Prior to disclosing any such proposed publications Publication, the publishing or presenting Party (or its applicable Affiliate) shall deliver a complete copy of the paper or materials for oral presentation to the other Party at least thirty (30) calendar days prior to disclosing the Publication. The other Party shall review any such Publication and give its comments, if any, (and, in the case of Licensee as the reviewing Party, notify POZEN whether or not it is granting its approval) to the publishing Party within fifteen (15) calendar days of the delivery of such Pfizerpaper to the other Party. With respect to oral presentation materials and abstracts, the reviewing Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing Party with appropriate comments, if any, but in no event later than fifteen (15) calendar days from the date of delivery to the reviewing Party. Failure by the reviewing Party to respond within such fifteen (15) calendar days shall be deemed approval to publish or present. The publishing or presenting Party (or its applicable Affiliate) shall consider the comments of the other Party in good faith and shall comply with the other Party’s request to delete references to such other Party’s Confidential Information relates to [ * ](or the Licensed Know-How, in the case of either Party as the reviewing Party) in any such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted Publication and filed separately with the Securities and Exchange Commission pursuant to Rule 406 shall withhold publication of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of any such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended Publication for an additional [ * ] sixty (60) calendar days in order to permit the Parties to obtain patent protection if either Party deems it necessary. Notwithstanding the foregoing, POZEN shall not request that Licensee delete references in Publications to clinical data owned by POZEN and contained in the event Pfizer canNDA for the Initial Products, within [ * ] of receipt which clinical data Licensee may freely publish. Any Publication shall include recognition of the written copycontributions of the other Party according to standard practice for assigning scientific credit, demonstrate reasonable need for such extension including either through authorship or acknowledgement, as may be appropriate. Each Party shall use Commercially Reasonable Efforts to cause investigators and institutions participating in pre-approval clinical studies, Phase IV Clinical Studies, Post-Approval Commitments or other clinical studies for the preparation and filing of patent applications. Iterum will comply Licensed Products with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties which it contracts (but excluding in each case any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free investigator-sponsored human clinical studies) to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant agree to Section 13.2 or by Iterum pursuant terms substantially similar to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures those set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)12.8, which efforts shall satisfy such Party’s obligations under this Section 12.8 with respect to such investigators and institutions.

Publications. Pfizer The Parties, through the JDC, shall not submit develop policies and procedures (“Publication Policies”) for any publication with respect to Development of any Licensed Compound or presentationLicensed Product, including the results of any clinical studies and disclosure in applicable clinical trial registries. The Publication Policies shall be consistent with each Party’s policies and procedures for the publication and disclosure of the results of clinical studies. Each Party recognizes that the publication of papers regarding results of, and other information regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties; provided that such publications are subject to [****] controls to protect Confidential Information. In particular, the Parties intend to maintain the confidentiality of any Confidential Information included in any invention disclosures or Patent application until such Patent application has been filed. Accordingly, AbbVie shall be free to publicly disclose the results of, and information regarding, activities under this Agreement in a manner consistent with Applicable Law and industry practices, as provided in this Section 8.7, subject to prior review by Licensor of any disclosure of Licensor’s Confidential Information for issues of patentability and protection of such Confidential Information. Before publishing or disclosing any of Licensor’s Confidential Information, AbbVie shall deliver a then-current copy of proposed abstracts, manuscripts or summaries of presentations to Licensor at [****] prior to submitting the paper to a publisher or an oral presentation is made. Licensor shall review any such paper and give its comments to AbbVie within [****] of the delivery of such paper to Licensor. With respect to oral presentation materials and abstracts, Licensor shall make [****] efforts to expedite review of such materials and abstracts, and shall return such items [****] practicable to AbbVie with [****] comments, [****], but in no event later [****] from the date of delivery to Licensor. Failure to respond within such [****] period shall be deemed approval to publish or present. Notwithstanding the foregoing, AbbVie shall comply with Licensor’s request to delete references to Licensor’s Confidential Information in any academic, scientific or medical publication such paper or presentation disclosing and will withhold publication of any such paper or any such presentation for an [****] in order to permit Licensor to obtain Patent protection if Licensor deems it necessary. Any publication shall include recognition of the contributions of the Licensor according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. Licensor shall not, and shall cause each of its Affiliates and its and their respective licensors and (sub)licensees not to, make any publications or public disclosures regarding the Licensed Know-How (to the extent such Compounds or Licensed Know-How is still Pfizer’s Products or any Confidential Information) Information of AbbVie without IterumAbbVie’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information).

Publications. Pfizer The JMAC (and prior to the establishment of the JMAC, the JRC (for Research-related publications) or the JDC (for Development-related publications)) (each of the JRC, JDC and the JMAC, the “Responsible Committee”) shall not submit establish publication review and approval procedures for this Collaboration consistent with the publication policies of both Parties. The Parties shall review and approve any publication by either Party or presentationits Affiliates or (sub)licensees relating to the Compounds or Collaboration Products, including scientific, health economic or publish or presentpharmacoeconomic publications, any academicin accordance with such procedures, considering Astellas’ and Cytokinetics’ interest in publishing the results of the work in the Research, Development, and Medical Affairs Activities in order to obtain recognition within the scientific or medical publication other applicable community and to advance the state of knowledge in the field, the need to protect Confidential Information and the Parties’ mutual interest in obtaining valid patent protection, protecting reasonable business interests and trade secret information, and having an integrated approach to developing one or presentation disclosing the Licensed Know-How (more Collaboration Products for one or more Indications. Consequently, except for disclosures permitted pursuant to Sections 13.3 and 13.5, each Party and their Affiliates, employee(s) and consultant(s) shall deliver to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer Responsible Committee for review and comment a copy of any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should that pertains to any Compound or Collaboration Product, pursuant to a procedure to be modified or deletedestablished by the Responsible Committee (but excluding general corporate publications and presentations), any such comments to be provided within [*] days of receipt. Pfizer The Responsible Committee shall have the right to approve require modifications of the publication or presentation: (a) to protect each Parties’ respective Confidential Information; (b) for trade secret reasons or business reasons; and/or (c) to delay such submission for an additional [*] days as may be reasonably necessary to seek patent protection for the information disclosed in such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * submission. [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information).

Publications. Pfizer shall not submit for Allergan recognizes that the publication or presentationof papers regarding results of and other Information regarding activities under this Agreement by Licensee, or publish or presentincluding oral presentations and abstracts, any academicmay be beneficial to both Parties, scientific or medical publication or presentation disclosing the Licensed Know-How (provided that such publications are subject to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not reasonable controls to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s protect Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer Accordingly, Allergan shall at all times have the right to review and approve any paper proposed for publication by Licensee, including any oral presentation or abstract, that contains Confidential Information of Allergan. Before any such proposed publications paper is submitted for publication or an oral presentation is made, Licensee shall deliver a complete copy of the paper or materials for oral presentation to Allergan at least [***] prior to submitting the paper to a publisher or making the presentation. Allergan shall review any such paper and give its comments to Licensee, and if applicable, notify Licensee whether Allergan approves of such Pfizerpaper, in each case within [***] after the delivery of such paper to Allergan. With respect to oral presentation materials and abstracts, Allergan shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to Licensee with appropriate comments, if any, but in no event later than [***] after the date of delivery to Allergan. Failure to respond within such [***] shall be deemed approval to publish or present. Notwithstanding the foregoing, Licensee shall comply with Allergan’s written request to (i) delete references to Allergan’s Confidential Information relates to [ * ], in any such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication paper or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for or (ii) withhold publication of any such paper or any presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended same for an additional [ * [***] in the event Pfizer can, within [ * ] of receipt order to permit Allergan to obtain patent protection if Allergan deems it necessary. Any publication shall include recognition of the written copycontributions of Allergan according to standard practice for assigning scientific credit, demonstrate either through authorship or acknowledgement, as may be appropriate. Licensee shall use commercially reasonable need for such extension including efforts to cause investigators and institutions participating in Clinical Trials for the preparation and filing of patent applications. Iterum will comply Licensed Products in the Field with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free which it contracts to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant agree to Section 13.2 or by Iterum pursuant terms substantially similar to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures those set forth in this Section 14.3 for publication 7.5, which efforts shall satisfy Licensee’s obligations under this Section 7.5 with respect to such investigators and institutions. Allergan shall not publish any paper regarding the Licensed Compound or presentation of Pfizer Confidential Information)any Licensed Product in the Field, including oral presentations and abstracts, without Licensee’s prior written consent.

Publications. Pfizer The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party (in such capacity the “Publishing Party”) agrees that, except as required by Applicable Laws, it shall not submit for publication or presentation, or publish or present, or permit to be published or presented, any academicresults of the Development, scientific Manufacture, use or medical publication or presentation disclosing the Commercialization of a Licensed Know-How (Product to the extent such results refer to, derive from or otherwise relate to the Licensed KnowIntellectual Property (the “Covered Results”), without the prior review by and approval of the other Party (in such capacity, the “Non-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentDisclosing Party”), such consent which approval shall not to be unreasonably withheld withheld; provided that it shall not be deemed unreasonable for ImmunoGen to withhold its consent to any request by CytomX to publish or delayeddisseminate Covered Results prior to the publication or dissemination of such Covered Results by ImmunoGen. During the Term, Iterum The Publishing Party shall submit to Pfizer the Non-Disclosing Party for review and approval any proposed academic, scientific or and medical publication or public presentation that which contains PfizerCovered Results or otherwise contains the Non-Disclosing Party’s Confidential Information; provided that the foregoing requirement shall apply to ImmunoGen only to the extent any such proposed publication or presentation would refer to, describe or otherwise disclose Confidential Information of CytomX (including, without limitation, any non-public Licensed Intellectual Property). Such In addition, each Party shall submit to the other Party for review and approval any proposed publication or public ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. presentation relating to data generated under the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology Intellectual Property and determining whether any portion of the proposed publication or presentation containing Pfizerthe Non-Disclosing Party’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * ] thirty (30) days before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * ] of fifteen (15) days after its receipt of such written copy, and the Publishing Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional [ * ] sixty (60) days in the event Pfizer the Non-Disclosing Party can, within [ * ] fifteen (15) days of receipt of the written copy, demonstrate reasonable need for such extension extension, including for the preparation and filing of patent applications. Iterum The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)6.3.2.

Publications. Pfizer The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party (in such capacity the “Publishing Party”) agrees that, except as required by Applicable Laws, it shall not submit for publication or presentation, or publish or present, or permit to be published or presented, any academic, scientific or medical publication or presentation disclosing results of the Licensed Know-How (Research Program to the extent such Licensed Knowresults refer to, derive from or otherwise relate to (a) in cases where CytomX is ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. the Publishing Party, the ImmunoGen Technology, (b) in cases where ImmunoGen is the Publishing Party, the CytomX Technology, and (c) in cases where either Party is the Publishing Party, the Joint Program Technology, the Agreement PDCs or the ImmunoGen Probodies (the “Covered Results”), without the prior review by and approval of the other Party (in such capacity, the “Non-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentDisclosing Party”), such consent which approval shall not to be unreasonably withheld withheld; provided that (i) it shall not be deemed unreasonable for CytomX to withhold its consent to any request by ImmunoGen to publish or delayeddisseminate Covered Results relating to CytomX Agreement PDCs prior to the publication or dissemination of such Covered Results by CytomX, and (ii) it shall not be deemed unreasonable for ImmunoGen to withhold its consent to any request by CytomX to publish or disseminate Covered Results relating to ImmunoGen Probodies and ImmunoGen Agreement PDCs prior to the publication or dissemination of such Covered Results by ImmunoGen. During the Term, Iterum The Publishing Party shall submit to Pfizer the Non-Disclosing Party for review and approval any proposed academic, scientific or and medical publication or public presentation that which contains PfizerCovered Results or otherwise contains the Non-Disclosing Party’s Confidential Information. Such In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed CytomX Technology and ImmunoGen Technology and determining whether any portion of the proposed publication or presentation containing Pfizerthe Non-Disclosing Party’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * ] sixty (60) days before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * ] of thirty (30) days after its receipt of such written copy, and the Publishing Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional [ * ] sixty (60) days in the event Pfizer the Non-Disclosing Party can, within [ * ] thirty (30) days of receipt of the written copy, demonstrate reasonable need for such extension extension, including for the preparation and filing of patent applications. Iterum The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)6.3.2.

Publications. Pfizer shall not submit for publication or presentation, or It is expected that each Party may wish to publish or present, any academic, scientific or medical publication or presentation disclosing otherwise publicly disclose the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value results of the Licensed Technology and determining whether any portion research under this Agreement. CURAGEN may publish the results of its Non-directed Research or Directed Research only after the expiration of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this documentExhibit, marked by bracketsbrackets and asterisks, has been were omitted and have been filed separately with the Securities and Exchange Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 24b-2 of the Securities Exchange Act of 1933, as amended1934. approval not Exclusive Evaluation Period and Option Periods applicable to be unreasonably withheld or delayed. Written copies the Clone that is the subject of such proposed publication publication, and only in accordance with the following provisions. In order to safeguard intellectual property rights, the Party wishing to publish or presentation required to be submitted otherwise publicly disclose the results of its research hereunder shall be submitted first submit a draft of the proposed manuscripts or disclosure to Pfizer no later than [ * the RC for each Party’s review, comment and consideration of appropriate patent action at least [*****] before prior to any submission for publication or presentation (the “Review Period”)other public disclosure. Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * Within [*****] of receipt of the written copyprepublication materials, demonstrate reasonable need the RC will advise the Party seeking publication as to whether a patent application will be prepared and filed or whether trade secret protection should be pursued and, if so, such Party will delay the submission of such publication or disclosure for such extension including for an additional [********] days to permit the preparation and filing of a patent applicationsapplication. Iterum will comply with standard academic practice regarding authorship . In no event shall a proposed publication be delayed for more than [********] days. If, during such [********], the RC does not advise the Party seeking publication that a patent application should be filed and the other Party does not prohibit publication of scientific publications and recognition of contribution of other parties certain information as provided below in any publication governed by this Section 14.34.2, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum the Party seeking publication shall be free to publish and present all Developed IP generated by such results. CURAGEN shall have the right to reasonably prohibit publications based primarily upon CURAGEN Projects. CURAGEN shall also have the right to reasonably prohibit publication of QEA/GeneCalling or on behalf MIM/PathCalling data. Each Party shall have the right to reasonably prohibit publication of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according own Confidential Information provided to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)other Party hereunder.